Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206.
Kenmotsu H, Niho S, Tsuboi M, Wakabayashi M, Ishii G, Nakagawa K, Daga H, Tanaka H, Saito H, Aokage K, Takahashi T, Menju T, Kasai T, Yoshino I, Minato K, Okada M, Eba J, Asamura H, Ohe Y, Watanabe SI. Kenmotsu H, et al. Among authors: wakabayashi m. J Clin Oncol. 2020 Dec 20;38(36):4292-4301. doi: 10.1200/JCO.20.01806. Epub 2020 Nov 2. J Clin Oncol. 2020. PMID: 33136471 Clinical Trial.
Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A).
Nomura M, Kato K, Ando N, Ohtsu A, Muro K, Igaki H, Abe T, Takeuchi H, Daiko H, Gotoh M, Kataoka K, Wakabayashi M, Kitagawa Y. Nomura M, et al. Among authors: wakabayashi m. Jpn J Clin Oncol. 2017 Jun 1;47(6):480-486. doi: 10.1093/jjco/hyx040. Jpn J Clin Oncol. 2017. PMID: 28334858 Clinical Trial.
Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
Sekine I, Harada H, Yamamoto N, Wakabayashi M, Murakami H, Goto K, Nogami N, Seto T, Oshita F, Okamoto H, Tanaka H, Tamura T, Ishikura S, Ohe Y. Sekine I, et al. Among authors: wakabayashi m. Lung Cancer. 2017 Jun;108:232-237. doi: 10.1016/j.lungcan.2017.04.002. Epub 2017 Apr 4. Lung Cancer. 2017. PMID: 28625642 Clinical Trial.
Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
Okuno T, Wakabayashi M, Kato K, Shinoda M, Katayama H, Igaki H, Tsubosa Y, Kojima T, Okabe H, Kimura Y, Kawano T, Kosugi S, Toh Y, Kato H, Nakamura K, Fukuda H, Ishikura S, Ando N, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Okuno T, et al. Among authors: wakabayashi m. Int J Clin Oncol. 2017 Dec;22(6):1042-1049. doi: 10.1007/s10147-017-1154-6. Epub 2017 Jul 17. Int J Clin Oncol. 2017. PMID: 28717855 Free PMC article. Clinical Trial.
A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III).
Miyamoto K, Ito A, Wakabayashi M, Eba J, Arai Y, Nishiyama H, Sugimoto M, Yamashita R, Kakehi Y. Miyamoto K, et al. Among authors: wakabayashi m. Jpn J Clin Oncol. 2018 Jan 1;48(1):94-97. doi: 10.1093/jjco/hyx158. Jpn J Clin Oncol. 2018. PMID: 29136187 Clinical Trial.
A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413).
Hishida T, Saji H, Watanabe SI, Asamura H, Aokage K, Mizutani T, Wakabayashi M, Shibata T, Okada M; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG). Hishida T, et al. Among authors: wakabayashi m. Jpn J Clin Oncol. 2018 Feb 1;48(2):190-194. doi: 10.1093/jjco/hyx170. Jpn J Clin Oncol. 2018. PMID: 29177507 Clinical Trial.
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Iida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, Kikukawa Y, Masaki Y, Kobayashi M, Hanamura I, Asai H, Nagai H, Shimada K, Tsukamoto N, Inoue Y, Tobinai K. Iida S, et al. Among authors: wakabayashi m. Cancer Sci. 2018 May;109(5):1552-1561. doi: 10.1111/cas.13550. Epub 2018 Apr 17. Cancer Sci. 2018. PMID: 29478257 Free PMC article. Clinical Trial.
High-Risk Factors for Recurrence of Stage I Lung Adenocarcinoma: Follow-up Data From JCOG0201.
Tsutani Y, Suzuki K, Koike T, Wakabayashi M, Mizutani T, Aokage K, Saji H, Nakagawa K, Zenke Y, Takamochi K, Ito H, Aoki T, Okami J, Yoshioka H, Okada M, Watanabe SI; Japan Clinical Oncology Group Lung Cancer Surgical Study Group (JCOG-LCSSG). Tsutani Y, et al. Among authors: wakabayashi m. Ann Thorac Surg. 2019 Nov;108(5):1484-1490. doi: 10.1016/j.athoracsur.2019.05.080. Epub 2019 Jul 20. Ann Thorac Surg. 2019. PMID: 31336067
Long-term survival outcome after lobectomy in patients with clinical T1 N0 lung cancer.
Ito H, Suzuki K, Mizutani T, Aokage K, Wakabayashi M, Fukuda H, Watanabe SI; Japan Clinical Oncology Group Lung Cancer Surgical Study Group. Ito H, et al. Among authors: wakabayashi m. J Thorac Cardiovasc Surg. 2020 Jan 11:S0022-5223(20)30054-4. doi: 10.1016/j.jtcvs.2019.12.072. Online ahead of print. J Thorac Cardiovasc Surg. 2020. PMID: 32067786 Free article.
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H, Kotani D, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukutani M, Togashi Y, Fuse N, Nishikawa H, Kojima T. Bando H, et al. Among authors: wakabayashi m. BMC Cancer. 2020 Apr 20;20(1):336. doi: 10.1186/s12885-020-06716-5. BMC Cancer. 2020. PMID: 32312286 Free PMC article. Clinical Trial.
594 results